BASEL, Switzerland, Dec. 19, 2006 (PRIME NEWSWIRE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) announced today the opening of two primary-treatment phase III clinical trials for isavuconazole (BAL8557) in patients with invasive systemic fungal infections caused by yeasts and molds. Isavuconazole is Basilea's third compound to enter phase III development.
